NCT02740985
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 130 Years (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: History of seizures, central nervous system tumors or CNS metastasis
https://ClinicalTrials.gov/show/NCT02740985